Teva Files Ninth Suit Over Heart Failure Drug

Law360, New York (June 25, 2007, 12:00 AM EDT) -- Teva Pharmaceutical Industries Ltd. has gone on the warpath ahead of the anticipated expiration of GlaxoSmithKline's pediatric exclusivity period for its congestive heart failure treatment Coreg, filing nine patent suits in less than a week over various defendants' plans to bring a generic version to the U.S. market.

Teva filed suit on Friday against Mumbai-based USV Ltd. in New Jersey, arguing that USV's plans to manufacture and sell Coreg's active pharmaceutical ingredient to third parties constitutes an imminent threat of infringement, and seeking declaratory judgment and...
To view the full article, register now.